Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03928899
Other study ID # PekingUFHIOL
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 15, 2019
Est. completion date December 31, 2022

Study information

Verified date September 2021
Source Peking University First Hospital
Contact Chen Wang
Phone 18518079870
Email wangchenpku@bjmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigatiors aimed to conduct a well-designed RCT to firstly focus on GDM women controlled with only diet and exercise, and provide an optimize process on their timing and mode of delivery


Description:

GDM is a common complication of pregnancy and even mildly hyperglycemia could significantly affect fetal growth. Optimal delivery timing in women with GDM remains controversial. This decision process involves balancing the potential for complications that are caused by increased interventions with the benefit of avoidance of future adverse outcomes. Thus, the aim of the present trial is to explore the best management on the timing of delivery of pregnant women with GDM that controlled with only diet and exercise, which can both decrease the risk of macrosomia and the risk of cesarean delivery.


Recruitment information / eligibility

Status Recruiting
Enrollment 230
Est. completion date December 31, 2022
Est. primary completion date May 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - singleton pregnant women - in vertex presentation - GDM that is controlled with only diet and exercise - at 37 weeks 0 days to 37 weeks 6 days of gestation - more than 18 years old - have no other contraindications to vaginal delivery. Exclusion Criteria: - prior caesarean section or myomectomy - any known contraindications to vaginal delivery - uncertain gestational age - non reassuring foetal wellbeing necessitating delivery - maternal pregnancy-related disease necessitating delivery (any hypertensive disorder, cardiac disease, renal insufficiency?immune diseases, et al.) - placenta previa, accreta, vasa previa - known foetal anomaly - negative reproductive history - ruptured membranes or known oligohydramnios (defined as AFI < 5 or MVP < 2 ) before 37weeks 6 days of gestation - fetal growth restriction, defined as EFW < 10th percentile - known HIV positivity because of modified delivery plan - signs of labor (regular painful contractions with cervical change) before 37weeks 6 days of gestation.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
New procedure
An optimal management on the timing and mode of delivery of pregnant women with GDM, by a comprehensive assessment and consideration of their fetal weight, gestational age, and cervical ripeness.

Locations

Country Name City State
China Peking University First Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Peking University First Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary caesarean section rate 41weeks
Secondary mode of delivery spontaneous or operative vaginal delivery, caesarean section;the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary onset of labour spontaneous or instrumental third stage of labour, planned or emergency caesarean section;the investigator will use questionnaire to collect these information 41weeks
Secondary operative vaginal delivery indication chorioamnionitis defined as a clinical diagnosis before delivery; fetal distress; arrest of second stage of labour; maternal complicatio;the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary caesarean section indication induction failed; chorioamnionitis defined as a clinical diagnosis before delivery; fetal distress; arrest of second stage of labour; failed instrumental delivery; maternal complication; elective 41weeks
Secondary method of induction of labour prostaglandin tablet regime; artificial rupture of amniotic membranes; oxytocin exclusive if used to accelerate normal labour 41weeks
Secondary indication for induction randomised to treatment; prelabour rupture of membranes > 2 hours and no regular contractions; fetal growth restriction; reduced fetal movements/suspected fetal distress; pregnancy induced hypertension; pre-eclampsia/eclampsia; obstetric cholestasis;the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary gestational age 41weeks
Secondary intrapartum complications placental abruption; cord prolapse; postpartum haemorrhage defined as bleeding of 500/1000ml or more in the first 24 hours following the vaginal/ caesarean section delivery of the baby; third or fourth degree perineal laceration; admission to intensive care unit; hysterectomy; maternal venous thromboembolism 41weeks
Secondary birth weight 41weeks
Secondary neonatal sex 41weeks
Secondary neonatal plasma glucose level collected 1-2h after delivery 41weeks
Secondary neonatal hypoglycemia 41weeks
Secondary stillbirth a baby delivered with no signs of life after24 completed weeks of pregnancy 41weeks
Secondary shoulder dystocia the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary death before discharge from hospital 41weeks
Secondary Apgar at 1 min, Apgar at 5 min, Apgar at 10 minutes 41weeks
Secondary cord blood artery pH 41weeks
Secondary neonatal respiratory distress the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary birth trauma subdural haematoma, intracerebral or intraventricular haemorrhage, spinal-cord injury, basal skull fracture, peripheral-nerve injury, long bone fracture 41weeks
Secondary NICU admission 41weeks
Secondary seizures the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary hypotonia the investigator will use questionnaire to collect these information from their medical record 41weeks
Secondary intubation and ventilation for > 24 h 41weeks
Secondary oxygen required 41weeks
Secondary the utilization of medical resources That includes: number of clinic visits post randomization to admission for delivery, number of times for having non-stress tests, ultrasounds and contraction stress tests, Use of induction and ripening agents, maximum dose of oxytocin, interval from randomization to delivery, number of hours on the labor and delivery unit, maternal postpartum length of hospital stay, neonatal length of hospital stay 41weeks
Secondary the mothers' expectations and experience of childbirth measured by the Labour Agentry Scale (which is designed to assess the expectations and experiences of personal control during childbirth, with higher scores indicating greater perceived control during childbirth) 41weeks
Secondary rate of labor pain 41weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05081037 - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS) N/A
Active, not recruiting NCT03249896 - Web/Smartphone-based Lifestyle Coaching Program in Pregnant Women With Gestational Diabetes N/A
Terminated NCT03749889 - Low Carb vs Normal Carb in Pregnancy N/A
Completed NCT03859193 - Education Nutritional Video for Gestational Diabetics N/A
Recruiting NCT05037526 - Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care in Pregnancy Outcomes N/A
Completed NCT06178250 - Placenta, Fetal Liver, Sectional Ductus Venosus Volumes Examined by Three-dimensional Ultrasound in the Second Trimester N/A
Not yet recruiting NCT06310356 - Continuous Glucose Monitoring for Women With Gestational Diabetes N/A
Not yet recruiting NCT06445530 - Nutrition Optimization and Community Upliftment for Postpartum Recovery N/A
Recruiting NCT02590016 - Glucose Control During Labour in Gestational Diabetes Mellitus With Insulin Treatment: A Randomized Controlled Trial Phase 4
Not yet recruiting NCT00883259 - Metformin and Gestational Diabetes in High-risk Patients: a RCTs Phase 4
Withdrawn NCT01947699 - Glycemic Profile in Women With Gestational Diabetes Treated With Glyburide Phase 4
Recruiting NCT03008824 - Micronutrients in Pregnancy as a Risk Factor for Diabetes and Effects on Mother and Baby N/A
Active, not recruiting NCT01340924 - Relationship Between Gestational Diabetes and Type 2 Diabetes
Completed NCT00534105 - Lipid Metabolism in Gestational Diabetes N/A
Recruiting NCT00371306 - Comparison of Glucovance to Insulin for Diabetes During Pregnancy N/A
Completed NCT03388723 - Intergenerational Programming of Diabesity in Offspring of Women With Gestational Diabetes Mellitus
Recruiting NCT04521712 - Postpartum Glycemia in Women at Risk For Persistent Hyperglycemia N/A
Enrolling by invitation NCT03307486 - Gestational Diabetes: a Cohort Study N/A
Active, not recruiting NCT03301792 - Group Versus Traditional Prenatal Care for Diabetes N/A
Enrolling by invitation NCT05603793 - YoUng Adolescents' behaViour, musculoskeletAl heAlth, Growth & Nutrition